Drug response marker in beta-1 adrenergic receptor gene
AssigneeMyriad Genetics, Inc.
InventorsFabiana Filigheddu, Julia Reid, Susanne Wagner
Life of this patent
Estimating the term…
Abstract
Methods of using a genetic polymorphic variation in the human beta-1 adrenergic receptor gene as a drug response marker are presented. Determining the presence or absence of the A145G genetic variation in the human beta-1 adrenergic receptor gene is useful in predicting an individual's relative response to different antihypertensive drugs; optimizing antihypertensive treatment for an individual; selecting candidate human subjects for participation in clinical trials involving antihypertensive drugs; and, predicting the relative responses among a plurality of individuals to an antihypertensive drug.
Claims24
A method for selecting an antihypertensive treatment for an individual, comprising:
- identifying an individual in need of an antihypertensive treatment;
- and
- determining the presence or absence of an A145G nucleotide variant or a nucleotide variant resulting in a Ser49Gly amino acid substitution in a nucleic acid of the individual encoding beta-1 adrenergic receptor, or the presence or absence of a Ser49Gly amino acid variant in the beta-1 adrenergic receptor protein of the individual.
A method for selecting an antihypertensive treatment for an individual, comprising:
- identifying an individual in need of an antihypertensive treatment;
- and
- determining the genotype of the individual at the nucleotide 145 position of the beta-1 adrenergic receptor gene.
A method for selecting an antihypertensive treatment for an individual, comprising:
- determining the genotype of the individual at the nucleotide 145 position of the beta-1 adrenergic receptor gene, wherein the presence of a homozygous A145G genetic variant would indicate an increased likelihood that said individual will respond more favorably to diuretic antihypertensive drugs than to angiotensin converting enzyme inhibitors and beta-blockers.
A method for selecting an antihypertensive treatment for an individual, comprising:
- determining the genotype of the individual at the nucleotide 145 position of the beta-1 adrenergic receptor gene, wherein the presence of a homozygous A145G genetic variant would indicate an increased likelihood that said individual will respond more favorably to hydrochlorothiazide than to fosinopril and atenolol.
A method of treating hypertension comprising:
- determining the genotype of the individual at the nucleotide 145 position of the beta-1 adrenergic receptor gene;
- selecting an antihypertensive drug for administration to the individual based on the genotype obtained in said determining step;
- and
- administering said drug to the individual or instructing the individual to take said drug.
A method for predicting the relative responses of an individual to different classes of antihypertensive drugs, said method comprising:
- determining, in an individual with hypertension, the presence or absence of an A145G nucleotide variant or a nucleotide variant resulting in a Ser49Gly amino acid substitution in a nucleic acid of the individual encoding beta-1 adrenergic receptor, or the presence or absence of a Ser49Gly amino acid variant in the beta-1 adrenergic receptor protein of the individual.
A method for predicting the relative responses of an individual to different drugs, said method comprising:
- genotyping an individual with hypertension to determine the genotype at the nucleotide 145 position of the beta-1 adrenergic receptor gene, wherein the presence of a homozygous A145G genetic variant or a homozygous genetic variant resulting in the Ser49Gly amino acid variant would indicate an increased likelihood that said individual will respond more favorably to hydrochlorothiazide than to fosinopril and atenolol.
A method for selecting candidate human subjects for participation in a clinical trial involving an antihypertensive drug, comprising:
- determining the genotype of an individual at the nucleotide 145 position of the beta-1 adrenergic receptor gene, and
- deciding whether to include said individual in the clinical trial based on the result of the determining step.
A method for manufacturing a transmittable form of information useful in predicting the relative response of an individual to different drugs, said method comprising:
- determining, in an individual with hypertension, the genotype at the nucleotide 145 position of the beta-1 adrenergic receptor gene, wherein the presence of a homozygous A145G genetic variant would indicate an increased likelihood that said individual will respond more favorably to diuretic antihypertensive drugs than to angiotensin converting enzyme inhibitors and beta-blockers;
- and
- embodying the genotype obtained in said determining step in a transmittable form.
Dependencies are inferred from the claim text.